Anavex Life Sciences (NASDAQ:AVXL) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Anavex Life Sciences (NASDAQ:AVXL) released its earnings results on Wednesday. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03, Zacks reports.

Anavex Life Sciences Price Performance

Shares of AVXL stock traded down $0.09 during trading hours on Wednesday, reaching $8.20. The company had a trading volume of 463,270 shares, compared to its average volume of 1,568,910. Anavex Life Sciences has a 12 month low of $3.25 and a 12 month high of $14.44. The company has a market cap of $695.44 million, a price-to-earnings ratio of -15.84 and a beta of 0.69. The business has a fifty day simple moving average of $9.93 and a 200-day simple moving average of $7.69.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on AVXL shares. D. Boral Capital restated a “buy” rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a report on Tuesday, January 28th.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.